The drug Zytiga, approved last year to treat metastatic prostate cancer, helped eliminate tumors in high-risk patients whose malignancy hadn’t yet spread, a small study found. Mary-Ellen Taplin, HMS associate professor of medicine at Dana Farber Cancer Institute, was the leader of the study.
